Zepbound is one of the most-prescribed weight-management drugs in America, but Medicare's coverage hinges entirely on why it is prescribed. Here is the full picture for 2026.
When does Medicare cover Zepbound?
Medicare Part D cannot pay for Zepbound (tirzepatide) when it is prescribed only for weight loss, because federal law excludes weight-loss-only drugs. However, a Part D plan that lists Zepbound on its formulary may cover it for an approved medical indication, such as moderate-to-severe obstructive sleep apnea in adults with obesity. Coverage is indication-specific, so the diagnosis on your prescription is decisive. Many plans also require prior authorization. To confirm whether your plan covers Zepbound for your situation, call 1-800-MEDIGAP at 1-800-633-4427 for a free formulary check.
How does the GLP-1 Bridge change Zepbound access in 2026?
Beginning July 1, 2026, CMS launched a temporary GLP-1 Bridge demonstration that, for the first time, lets eligible Medicare Part D members get Zepbound (KwikPen) for obesity at a flat $50 copay per 30-day supply, running through December 31, 2027. To qualify you generally need a BMI of 35 or higher, or a BMI of 30 to 34.99 with a condition like diastolic heart failure or uncontrolled high blood pressure. The $50 copay does not count toward your deductible or the $2,100 out-of-pocket cap, and single-dose vials are not included.
What will Zepbound cost me on Medicare?
Your Zepbound cost depends on the path. Through the GLP-1 Bridge, eligible members pay a flat $50 per 30-day KwikPen supply. When Zepbound is covered under standard Part D for an approved medical condition, you pay your plan's tier cost-sharing, which counts toward the 2026 $2,100 annual out-of-pocket cap. Without coverage, the cash price runs many hundreds of dollars a month. Because plans differ widely, a free review at 1-800-MEDIGAP can show you the lowest-cost route for your specific diagnosis and plan.